A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Concizumab (Primary) ; Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Acronyms explorer™4
- Sponsors Novo Nordisk
- 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2018 The study has been discontinued in Greece
- 11 Aug 2017 Status changed from not yet recruiting to recruiting.